Enbrel Pédiatrie

Quick links

Choose a section

Quick links to important sections

Advertisements

Enbrel Pédiatrie

Advertisements
Advertisements

Overview of Enbrel Pédiatrie

Quick Facts

Property Description
Active ingredient Etanercept (INN)
Form Solution for injection
Pharmacological class Immunosuppressant, TNF-alpha Inhibitor
General Purpose To neutralize inflammatory signals (TNF)
Origin Recombinant fusion protein (Biologic)
Patient Group Pediatric (children and adolescents)

What Type of Medicine is Enbrel Pédiatrie (Etanercept)?

Enbrel Pédiatrie is a specialized biologic medicine specifically formulated for pediatric patients, distinguishing its intended user group from general adult formulations. Its active component, Etanercept, is a complex protein manufactured using recombinant DNA technology, not chemical synthesis, which is a hallmark of biologic products. Etanercept is formally classified as a systemic Immunosuppressant and belongs to the class of Tumor Necrosis Factor alpha (TNF-alpha) inhibitors. This is a prescription-only product supplied as an aqueous solution for injection in pre-filled devices designed for subcutaneous administration.

The Composition and Origin of Etanercept

The active substance, Etanercept, is a recombinant fusion protein that is entirely synthetically derived, yet structurally mimics a naturally occurring receptor. This complex composition is clinically recognized for its ability to target specific inflammatory messengers, involving fusing the binding portion of the human p75 TNF receptor to the Fc portion of a human IgG1 antibody. The structure of this fusion protein ensures it acts as a highly effective decoy receptor.

What is the General Purpose of This Biologic Therapy?

The general purpose of this therapy is to provide foundational disease control by intercepting a primary driver of inflammation in the body. Etanercept achieves this as a TNF-alpha blocker, physically binding to and neutralizing the circulating Tumor Necrosis Factor protein. By capturing this inflammatory messenger, the therapy limits the chronic immune over-activity and the subsequent tissue damage it can cause; this action is designed to reduce the signs of persistent inflammation.

Regulatory References

  1. EMA Enbrel EPAR
  2. EMA Public Assessment Report (EPAR)
Advertisements

What side effects are possible with Enbrel Pédiatrie?

Possible Side Effects and Safety Information

The safety profile of Etanercept is defined by regulatory authorities through specific classifications of adverse reactions, categorized by frequency and the body's organ systems involved. This information is derived from comprehensive clinical data and post-marketing surveillance, providing a foundation for understanding the therapy's risk characteristics.

Frequency-Classified Adverse Reactions

The most frequently reported effects, designated as Very Common (occurring in more than 1 in 10 patients), include infections (such as upper respiratory tract infections) and injection site reactions (ISRs), which may involve erythema, pain, or swelling. Common reactions (up to 1 in 10 patients) include headache, fever, and certain allergic reactions. Reactions classified as Uncommon or Rare include more serious events.

Classification Examples of Adverse Reactions (SOC)
Very Common Infections, Injection Site Reactions
Rare Aplastic Anemia, Demyelinating Events

Serious Adverse Reactions and Safety Considerations

Treatment has been associated with a documented risk of serious infections, including sepsis, pneumonia, and the reactivation of latent Tuberculosis. The official prescribing information also highlights the occurrence of malignancies, including lymphoma and other cancers, in the pediatric population. Rare but serious effects involve the blood and lymphatic system (e.g., aplastic anemia) and the nervous system (e.g., demyelinating disorders).

Safety-related restrictions explicitly state that the medicine should not be initiated in patients with an active serious infection. Safety data indicate that injection site reactions are most frequently observed during the first month of treatment.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose with Enbrel Pédiatrie (Etanercept) is based on official government regulatory documents.

Documented Overdose Profile

Clinical trials have established that no dose-limiting toxicity was observed even when single doses of Etanercept were administered at an exposure level equivalent to three to six times the recommended adult therapeutic dose. Regulatory labeling does not document a specific, unique set of severe or life-threatening symptoms directly resulting from an acute overdose of this biologic medicine.

Overdose Context Regulatory Statement
Toxicity Classification No specific dose-limiting toxicity observed.
Antidote Availability No specific antidote is known for Etanercept.
Required Management Should consist of providing symptomatic and supportive treatment.

When to Seek Immediate Medical Help

In the event of a known or suspected overdose of Etanercept, it is mandated by health authorities that you seek immediate medical attention. Immediate contact should be made with emergency services or a poison control center for professional assessment and guidance. Management of the overdose will focus on supportive measures and clinical monitoring, as this approach is required due to the absence of a known specific antidote. Regulatory documents confirm that no specific population-based risk for overdose severity, including in the pediatric group, is documented separately from the general population.

Advertisements

Therapeutic Uses of Enbrel Pédiatrie

What Enbrel Pédiatrie Treats: Main Uses and Benefits

Enbrel Pédiatrie (Etanercept) is a systemic biologic therapy generally used in children and adolescents who have moderately to severely active inflammatory diseases. It is commonly used when supportive symptomatic assistance is needed in settings marked by temporary physiological imbalance. This medicine is applied across therapeutic domains where additional support is needed to address chronic symptoms related to inflammatory or irritative states. The therapy is commonly used to help with conditions presenting with systemic or localized discomfort, including the management of Juvenile Idiopathic Arthritis (JIA) and certain forms of chronic plaque psoriasis.

The medicine is used to address symptom clusters that interfere with daily functioning in conditions like polyarticular JIA, extended oligoarthritis, and severe chronic plaque psoriasis. The therapy may be part of symptomatic management in clinical settings marked by increased discomfort and chronic joint disease activity.

Managing Symptom Domains

This medicine is applied across domains involving chronic symptoms such as joint swelling, persistent pain, and morning stiffness associated with arthritis. It is also relevant for easing challenging skin manifestations, specifically the thick, scaly, and red plaques seen in severe psoriasis. The therapy provides support that helps ease the overall symptom burden, and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Chronic Inflammation
Primary Focus Chronic joint and systemic inflammation
Use Scenario Treatment-resistant, moderate-to-severe disease
Patient Benefit Easing overall symptom load and supporting physical function
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Enbrel Pédiatrie (Etanercept) — Official Regulatory Information

Category Official Regulatory Statement
Contraindicated Populations Patients with sepsis or those with a known hypersensitivity to the active substance or its excipients.
Treatment must not be initiated in patients with an active, serious infection, including chronic or clinically important localized infections.
Age-Related Eligibility Use is authorized for polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged mathbf2 years and older.
The safety and efficacy in children under 2 years of age have not been established.
The minimum age for pediatric plaque psoriasis is mathbf4 years (FDA) or mathbf6 years (EMA).
Conditional Restrictions Use is not recommended in patients with New York Heart Association (NYHA) functional Class III or IV congestive heart failure.
Caution is required for patients with a pre-existing or recent onset of a CNS demyelinating disorder or a history of recurrent infections.
Renal and Hepatic Impairment require no specific dose adjustment.
Pregnancy and Lactation Status Pregnancy: Use is not recommended. Contraception should be used during therapy and for three weeks following the last dose.
Lactation: It is not recommended while breastfeeding.

The regulatory profile strictly defines eligible use by excluding populations with contraindications such as sepsis and active infection. Treatment is confined to specific pediatric age thresholds (minimum 2 years for JIA) and requires caution in patients with certain comorbidities like severe heart failure or demyelinating conditions, as documented in official prescribing information.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Enbrel Pédiatrie (Etanercept) is primarily characterized by pharmacodynamic effects related to its immunosuppressive action, rather than metabolic changes; no specific CYP-enzyme or drug transporter interactions are documented in regulatory sources.

Contraindicated and Not Recommended Combinations

Co-administration with other specific immunosuppressants like Anakinra and Abatacept is not recommended due to the officially documented increased risk of serious infection and other serious adverse events. Administration of Live Vaccines is contraindicated while on Etanercept treatment and for a required period of four weeks following treatment discontinuation. A specific regulatory restriction notes that co-administration with Cyclophosphamide is not recommended in patients with Granulomatosis with Polyangiitis due to a documented increased risk of malignancy.

Co-administration Cautions

The co-administration of Etanercept with other TNF blockers or other general immunosuppressants is associated with an additive risk of serious infection. A functional interaction is documented with antidiabetic medications, where Etanercept may increase the effect of these drugs, carrying a risk of hypoglycemia. For pediatric patients, the continued co-administration of Glucocorticoids, NSAIDs, or Analgesics is generally allowed as specified in regulatory information.

Advertisements

Mechanism of Action

How Enbrel Pédiatrie Works

Enbrel Pédiatrie (Etanercept) is a biologic therapy that employs a mechanism known as competitive inhibition to modulate the body's inflammatory signaling. The core function is to neutralize specific signaling proteins that drive chronic inflammation, contributing to physiological changes at the tissue level.


Neutralizing Key Pro-Inflammatory Messengers

The drug functions as a soluble decoy receptor specifically engineered to bind to the circulating proteins, Tumor Necrosis Factor-alpha (TNF-alpha) and Lymphotoxin alpha (TNF-beta). By physically capturing these messengers, Etanercept prevents them from binding to their native cell-surface receptors. This neutralization immediately removes a primary driver of the inflammatory cascade, resulting in a modulation of systemic inflammatory signaling.


Interrupting the Destructive Cellular Cascade

Blocking the TNF-alpha signal prevents the activation of crucial intracellular pathways (like NF-kappaB) that dictate cellular responses. This interruption suppresses the gene expression that leads to the production of additional inflammatory mediators, such as chemokines and tissue-degrading enzymes (matrix metalloproteinases). The physiological consequence is a reduction in the chemical signals that recruit and sustain the migration of immune cells into affected tissues, contributing to the modulation of destructive biochemical processes.

Advertisements

Dosage and Administration Information

How to use Enbrel Pédiatrie — Administration Guidelines

Enbrel Pédiatrie is designated for administration solely via subcutaneous injection (SC). The medicine is generally administered on a once-weekly schedule, establishing the standardized treatment pattern.

Administration Scope Detail
Route of Administration Subcutaneous injection (SC). This is the only approved route for use.
Dosing Schedule The standard regimen is calculated by weight: 0.8 mg/kg per dose, with a maximum limit of 50 mg per week. Patients weighing 63 kg or more are generally administered the fixed dose of 50 mg once weekly.
Frequency Pattern Once weekly. For certain indications like Juvenile Idiopathic Arthritis (JIA), an alternative regimen specifies 0.4 mg/kg given twice weekly.
Preparation Requirements Before administration, the solution must be allowed to reach room temperature (approximately 15 to 30 minutes). It is a key instruction that the solution must not be shaken. The lyophilized powder formulation requires reconstitution with the provided diluent.
Age-Group Rules The medicine is used in pediatric patients with JIA 2 years of age and older, and for severe chronic plaque psoriasis in children 4 years of age and older. No specific dose adjustment is required for patients with documented renal or hepatic impairment.
Special Conditions The injection site must be rotated among the abdomen, thigh, and outer upper arm to ensure proper absorption. The medicine should not be injected into skin that is tender, bruised, red, hard, or otherwise compromised, including areas affected by psoriasis lesions.

The overall usage protocol defines a precise route (subcutaneous) and a strict frequency (once weekly), governed by a weight-dependent calculation up to a maximum 50 mg dose. This structure ensures standardized and measured delivery. Patients and caregivers are required to follow a protocol for handling, which includes not shaking the solution and observing site rotation rules.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Enbrel Pédiatrie

Evidence for Use in Juvenile Idiopathic Arthritis (JIA)

Research exploring how symptoms change over time in JIA primarily consists of short-term randomized controlled trials (RCTs). These studies were evaluated in children and adolescents, typically aged 4 to 17 years, with JIA characterized by conditions marked by functional limitations and chronic joint inflammation. The studies predominantly focused on populations that included those with previous inadequate response or intolerance to Methotrexate. Researchers monitored outcomes related to physical discomfort, such as the number of swollen or tender joints, and patient-reported outcomes describing perceived discomfort.

In these core trials, research explored whether patients in the study group exhibited different patterns of disease activity measurements compared to those in the non-active control group. Long-term observational cohort studies and patient registry data were evaluated in research examining temporary physiological imbalance for many years. These studies research describes patterns related to the maintenance of joint status and function measurements, noting that these findings are derived from non-randomized settings.


Evidence for Use in Chronic Severe Plaque Psoriasis

The research base for severe plaque psoriasis in children and adolescents consists of short-term, placebo-controlled clinical trials used in trials assessing short-term or episodic symptom patterns. The controlled research studies monitored specific patterns of change in measurements of skin severity and clearance in the observed populations over the initial 12 weeks of the study period compared to the measurements observed in the placebo group.

Follow-up research studies report how symptoms evolved in the observed populations in open-label extension periods, with maintained measurements described for up to 96 weeks. However, the initial controlled studies were of a short duration, meaning there is limited information for long-term outcomes through controlled evidence. Additionally, sample sizes were modest in the core trials for this pediatric condition.


Evidence in Specific Pediatric and Subgroup Populations

The available evidence was studied for children across a specific age range, most commonly starting from age 4 and up to 17 years. The studies predominantly focused on populations that included those with previous inadequate response or intolerance to Methotrexate. For instance, children under the age of four years were not included in the main controlled trials, and the available research for this very young group is limited.


What is Still Uncertain in the Research Record

The evidence landscape contains several limitations and gaps. Comparative evidence is lacking for many long-term outcomes, meaning that the research does not definitively detail how the medicine's measurements compare to those of other modern biologic therapies in pediatric patients over many years. Follow-up durations were limited in the gold-standard randomized controlled trials, and data for certain subtypes are still emerging.

Key Studies & References Australian Public Assessment Report for Etanercept (TGA) - Paediatric Psoriasis Indication

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Enbrel Pédiatrie (FAQ)

Q: Can Enbrel Pédiatrie reactivate a previously inactive viral infection, such as Hepatitis B?

Regulatory documents note that the use of TNF blockers, including Enbrel, has been associated with the reactivation of Hepatitis B in patients who were previously infected with the virus. Because of this risk, official product information notes that monitoring is required for patients with a current or prior Hepatitis B infection during and for several months after treatment.


Q: Are there any reported long-term safety concerns regarding cancer risk in children treated with TNF blockers?

Official warnings state that cases of lymphoma and other malignancies (cancers), some of which were fatal, have been reported in children and adolescents treated with TNF blockers. This information is detailed in the official safety warnings for this class of medicine.


Q: Can a child receive the standard seasonal influenza shot while on this treatment?

Official product guidance advises that the use of live vaccines is generally avoided during treatment with Enbrel. The standard seasonal influenza shot is typically a non-live vaccine, but official information indicates that the immune response to any non-live vaccine may be reduced while a child is taking this medicine.


Q: Is it common for patients to develop headaches after starting Enbrel Pédiatrie?

Headache is listed in clinical studies as a Common adverse reaction. According to official regulatory summaries, 'Common' generally means that the reaction has been observed to occur in up to 1 out of every 10 patients.


Q: What kind of specialist typically prescribes and manages a child's treatment with Enbrel Pédiatrie?

The European Summary of Product Characteristics (SmPC) states that treatment with Enbrel should be started and overseen by specialist physicians. These specialists should be experienced in the diagnosis and management of the conditions the medicine is approved to treat, such as juvenile idiopathic arthritis or pediatric plaque psoriasis.


Q: How long does it usually take to see the first signs of improvement with Enbrel Pédiatrie?

Studies indicate that the effects of the medicine are generally assessed over the initial weeks to months of treatment. For example, clinical trials for plaque psoriasis monitored changes over the initial 12 weeks of the study period.


Q: Is it necessary to allow the injection to warm up before giving it to the child?

Yes, the official Instructions for Use require that the solution must be allowed to reach room temperature before it is administered. Official instructions specify a preparation time, typically 15 to 30 minutes, to reach room temperature.


Q: Can the treatment affect a child's growth or development over time?

Studies examining the use of Enbrel in children with juvenile idiopathic arthritis (JIA) have indicated that treatment may help in the restoration of normal growth patterns (height and weight). This is consistent with the goal of managing chronic inflammatory conditions.


Q: What happens to the dose if a child's weight changes significantly?

For pediatric patients under 63 kg, the dose is calculated based on body weight (0.8 mg/kg weekly). Therefore, as a child grows and experiences significant weight changes, the prescribed dose will typically be adjusted by the specialist to match the child’s current weight.


Q: What should a parent do if their child develops a high fever close to the scheduled injection time?

The regulatory label instructs that Enbrel should not be started during an active, serious infection. If a child develops symptoms of an infection, such as a high fever, regulatory guidance indicates that treatment may need to be withheld if a child develops signs of a significant infection.


Q: Is it possible for a child to develop new or worsening psoriasis while on this medication?

Official prescribing information includes post-marketing reports of new-onset and worsening psoriasis in patients taking TNF-blocking agents. This is an example of a paradoxical adverse event, meaning the drug can cause a condition it is also used to treat.


Q: Are there reported side effects related to the nervous system, such as tingling, numbness, or dizziness?

While serious neurological events like demyelinating disorders are noted, postmarketing experience also includes less common nervous system reactions. These include paresthesias (tingling or numbness) and dizziness.


Q: Can non-prescription pain relievers interfere with the effects of Enbrel Pédiatrie?

The official product labeling specifically notes that common non-prescription pain relievers, such as NSAIDs or analgesics, may generally be continued during treatment with Enbrel in children with juvenile idiopathic arthritis.


Q: Is there a known interaction between Enbrel Pédiatrie and other biologic medicines?

Yes, official guidance advises that co-administration with other TNF blockers, or specific biologics like Anakinra and Abatacept, is not recommended. This is due to a documented increased risk of serious adverse events, including serious infection.


Q: What should happen regarding treatment if a child needs to have surgery?

The decision to interrupt treatment for elective surgery must be made by the specialist physician. This decision involves carefully balancing the potential risk of post-operative infection, which may be increased by the medicine, against the risk of the child's underlying disease flaring up if treatment is paused.


Q: Is Enbrel Pédiatrie ever used for conditions like uveitis or other eye inflammation associated with JIA?

Enbrel is officially indicated for the treatment of Polyarticular Juvenile Idiopathic Arthritis (JIA) and chronic plaque psoriasis. The regulatory labels define its approved use as Polyarticular JIA and chronic plaque psoriasis.

Advertisements

How should Enbrel Pédiatrie be stored and disposed of?

Storage and Disposal of Enbrel (Etanercept)

Enbrel is a temperature-sensitive biologic medicine requiring strict storage protocols to maintain its stability.


Storage Requirements

Condition Requirement
Primary Temperature Store refrigerated at 36 F to 46 F (mathbf2 C to mathbf8 C).
Freezing Do not freeze the medicine; discard if it has been frozen.
Alternative Storage May be stored at room temperature (mathbf68 F to mathbf77 F) for a single period of up to 30 days; do not return to refrigerator.
Light Protection Keep in the original carton to protect from light.
Safety Keep Enbrel and all medicines out of the reach of children.

Disposal

Used injection materials (needles, syringes) must be disposed of in an approved sharps container. Disposal of unused or expired product must be managed according to applicable local waste disposal regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enbrel Pédiatrie found in:

A-Z Index: